Middle East Pharmaceutical Industries Co. (4016.SR)
SAR 131.6
(0.3%)
SAR 131.6
(0.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 138.49 Million SAR | -14.6% |
| 2022 | 162.17 Million SAR | 8.23% |
| 2021 | 149.84 Million SAR | 26.77% |
| 2020 | 118.2 Million SAR | 79.37% |
| 2019 | 65.89 Million SAR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 140.34 Million SAR | 1.33% |
| 2024 Q2 | 128.8 Million SAR | -8.22% |
| 2023 Q4 | 138.49 Million SAR | 0.0% |
| 2023 Q1 | - SAR | -100.0% |
| 2023 Q3 | 138.49 Million SAR | -6.62% |
| 2023 Q2 | 148.32 Million SAR | 0.0% |
| 2023 FY | 138.49 Million SAR | -14.6% |
| 2022 Q3 | 162.17 Million SAR | 0.0% |
| 2022 FY | 162.17 Million SAR | 8.23% |
| 2022 Q4 | 162.17 Million SAR | 0.0% |
| 2022 Q1 | - SAR | 0.0% |
| 2021 FY | 149.84 Million SAR | 26.77% |
| 2020 FY | 118.2 Million SAR | 79.37% |
| 2019 FY | 65.89 Million SAR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Al-Dawaa Medical Services Company | 3.39 Billion SAR | 95.92% |
| Nahdi Medical Company | 2.9 Billion SAR | 95.238% |
| Al-Razi Medical Co. | 23.04 Million SAR | -500.908% |
| Almujtama Alraida Medical Co. | 312.21 Million SAR | 55.64% |